These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 2461688)

  • 1. Distinguishing features of idiopathic flushing and carcinoid syndrome.
    Aldrich LB; Moattari AR; Vinik AI
    Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pronounced flush symptoms in carcinoid syndrome without liver metastases].
    Roth J; Raschka C; Hammar CH
    Leber Magen Darm; 1994 Nov; 24(6):259-61. PubMed ID: 7531269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiological causes and clinical significance of flushing.
    Ray D; Williams G
    Br J Hosp Med; 1993 Nov 17-Dec 14; 50(10):594-8. PubMed ID: 8293240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoid syndrome. Medical management.
    Clarke B; Hodgson HJ
    Br J Hosp Med; 1986 Mar; 35(3):146-8, 150, 152. PubMed ID: 3742126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flush symptoms caused by a mesenteric carcinoid without liver metastases.
    Sonnet S; Wiesner W
    JBR-BTR; 2002; 85(5):254-6. PubMed ID: 12463502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical assessment of niacin deficiency among carcinoid cancer patients.
    Shah GM; Shah RG; Veillette H; Kirkland JB; Pasieka JL; Warner RR
    Am J Gastroenterol; 2005 Oct; 100(10):2307-14. PubMed ID: 16181385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.
    Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K
    J Clin Endocrinol Metab; 1986 Sep; 63(3):605-12. PubMed ID: 2426299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
    Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flushing in the carcinoid syndrome and plasma kallikrein.
    Lucas KJ; Feldman JM
    Cancer; 1986 Nov; 58(10):2290-3. PubMed ID: 2428458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary carcinoid tumor of the bilateral testis associated with carcinoid syndrome.
    Son HY; Ra SW; Jeong JO; Koh EH; Lee HI; Koh JM; Kim WB; Park JY; Shong YK; Lee KU; Kim GS; Kim MS
    Int J Urol; 2004 Nov; 11(11):1041-3. PubMed ID: 15509216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The carcinoid syndrome.
    Maton PN
    JAMA; 1988 Sep; 260(11):1602-5. PubMed ID: 2457717
    [No Abstract]   [Full Text] [Related]  

  • 17. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites.
    Matuchansky C; Launay JM
    Gastroenterology; 1995 Mar; 108(3):743-51. PubMed ID: 7533112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmic manifestations of the carcinoid flush.
    Wong VG; Melmon KL
    N Engl J Med; 1967 Aug; 277(8):406-9. PubMed ID: 4378294
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.